Drug Type Chemical drugs |
Synonyms- |
Target |
Action modulators |
Mechanism LRRK2 modulators(Leucine-rich repeat serine/threonine-protein kinase 2 modulators), α-synuclein modulators(Synuclein alpha modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Parkinson Disease | Preclinical | United States | 04 Aug 2024 |





